Ideaya Biosciences Inc
IDYAHealthcare·Biotechnology·USA·Mid·NASD·Nov 12 • 3:59 PM ET
31.49-1.23 (-3.74%)
2026-11-13 13:39 CET
Market cap
$3.04B
Revenue, TTM
36.53 USD m
Net income, TTM
-420.01 USD m
Free cash flow, TTM
-349.80 USD m
EPS diluted, TTM
-4.49
Price
IDYA against its 20, 50 and 200-day averagesPatternshover a marker to name it
26.2% under the 52-week high of 42.68 on 25 Aug 2026. 52-week low 26.81 on 10 Jun 2026. Last 15 sessions, 19.4% high to low
Volume 0.00× normal · the session has not printed · the line is the 50-bar volume average
Setup. RS line 60
CANSLIM 2 of 6 — fails: EPS Growth Qtr Over Qtr: High (>25%); EPS Growth This Year: High (>25%); 52-Week High/Low: 0-10% below High; Performance: Year +50%
VCP 4 of 6 — fails: 200-Day Simple Moving Average: Price above SMA200; 52-Week High/Low: 0-10% below High
Minervini 1 of 4 — fails: 200-Day Simple Moving Average: Price above SMA200; 52-Week High/Low: 0-10% below High; Performance: Year +50%
Zanger 0 of 5 — fails: RSI (14): Not Oversold (>50); Performance: Week +10%; 20-Day High/Low: 0-5% below High; Relative Volume: Over 1.5; 200-Day Simple Moving Average: Price above SMA200
Leaders 1 of 5 — fails: 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%; 52-Week High/Low: 0-10% below High
Breakout 0 of 4 — fails: 52-Week High/Low: New High; Relative Volume: Over 2; 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200
Growth 0 of 4 — fails: EPS Growth Qtr Over Qtr: High (>25%); EPS Growth This Year: High (>25%); EPS Growth Next Year: High (>25%); Return on Equity: Over +15%
Quality 2 of 5 — fails: Return on Equity: Over +15%; Net Profit Margin: High (>20%) — not on the tape: P/E: Under 25
Value 1 of 4 — fails: P/B: Under 2; Return on Equity: Over +15% — not on the tape: P/E: Under 15
Income 0 of 4 — fails: Dividend Growth: Growing 2+ Years — not on the tape: Dividend Yield: Over 2%; Payout Ratio: Low (<20%); P/E: Under 25
Small Cap 2 of 4 — fails: 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%
Accumulation 1 of 4 — fails: Institutional Transactions: Over +10%; 200-Day Simple Moving Average: Price above SMA200; Performance: Year Up
Relative Strength 1 of 3 — fails: Performance: Year +100%; 200-Day Simple Moving Average: Price above SMA200
Profile
IDYA52-week range, 29% of the way up
26.8142.68
IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically defined cancers having GNAQ and GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.
| Index | RUT |
|---|---|
| Employees | 145 |
| IPO | May 23, 2019 |
| Beta | 0.08 |
| ATR, 14d | 1.44 |
| Rel volume | 0.00 |
| Short float | 9.12% |
| Insider own | 6.64% |
| Inst own | 101.50% |
Snapshot
6 groupsValuation
| Index | RUT |
|---|---|
| Market Cap | $3.04B |
| Enterprise Value | 2.24B |
| Income | -420.01M |
| Sales | 36.53M |
| Book / share | 11.30 |
| Cash / share | 8.67 |
| Dividend Est. | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Dividend Gr. 3/5Y | - - |
| Payout | - |
| Employees | 145 |
| IPO | May 23, 2019 |
Ratios
| Price / earnings | - |
|---|---|
| Forward price / earnings | - |
| Price / earnings / growth | - |
| Price / sales | 83.35 |
| Price / book | 2.79 |
| Price / cash | 3.63 |
| Price / free cash flow | - |
| Value / cash profit | - |
| Value / sales | 61.21 |
| Quick Ratio | 9.04 |
| Current Ratio | 9.04 |
| Debt / equity | 0.03 |
| Long-term debt / equity | 0.03 |
| Options and short | Yes / Yes |
Earnings
| Earnings / share | -4.49 |
|---|---|
| Earnings next year | -4.36 |
| Earnings next quarter | -1.17 |
| Earnings this year | -268.96% |
| Earnings next year | 7.66% |
| Earnings growth, 5 years | - |
| Past earnings growth | 3.17% 1.64% |
| Past sales growth | 62.54% 62.11% |
| Earnings vs last year | -144.53% |
| Sales vs last year | -82.99% |
| Earnings vs last quarter | -191.88% |
| Sales vs last quarter | -95.07% |
| Earnings | Nov 03 BMO |
| Surprise | -3.43% 35.06% |
Ownership
| Insiders own | 6.64% |
|---|---|
| Insider trades | -0.56% |
| Institutions own | 101.50% |
| Institution trades | 4.96% |
| Return on assets | -34.98% |
| Return on equity | -38.46% |
| Return on capital | -37.51% |
| Gross Margin | 87.67% |
| Operating margin | -1267.38% |
| Profit Margin | -1149.62% |
| 20-day average | -4.39% |
| 50-day average | -11.62% |
| 200-day average | -6.99% |
Technical
| Shares out | 96.65M |
|---|---|
| Shares floating | 90.27M |
| Short / float | 9.12% |
| Short ratio | 9.28 |
| Short interest | 8.24M |
| 52-week high | 42.68 -26.2% |
| 52-week low | 26.81 +17.5% |
| Volatility | 4.00% 4.48% |
| Average range | 1.44 |
| Strength index | 40.56 |
| Market sensitivity | 0.08 |
| Relative volume | 0.00 |
| Avg Volume | 887.96K |
| Volume | 0 |
Performance
| Perf Week | 2.74% |
|---|---|
| Perf Month | -7.00% |
| Perf Quarter | -13.25% |
| Perf Half Y | 9.19% |
| Perf YTD | -8.91% |
| Perf Year | -1.44% |
| Perf 3Y | 7.15% |
| Perf 5Y | 36.73% |
| Perf 10Y | - |
| Recommendation | 1.12 |
| Target Price | 50.69 |
| Prev Close | 31.49 |
| Price | 31.49 |
| Change % | 0.00% |
Analyst ratings
latest 10 of 20| Date | Action | Analyst | Rating change | Target | Implied |
|---|---|---|---|---|---|
| Oct 16, 2026 | Initiated | William Blair | Outperform | ||
| Oct 14, 2026 | Resumed | Stifel | Buy | $48 | +52.4% |
| Jan 07, 2026 | Resumed | UBS | Buy | $50 | +58.8% |
| Nov 24, 2025 | Initiated | Truist | Buy | ||
| Sep 18, 2025 | Initiated | Guggenheim | Buy | $50 | +58.8% |
| Sep 04, 2025 | Initiated | Citizens JMP | Mkt Outperform | $41 | +30.2% |
| Sep 04, 2025 | Initiated | Barclays | Overweight | $40 | +27.0% |
| Jul 22, 2025 | Initiated | TD Cowen | Buy | ||
| Jul 10, 2025 | Resumed | Goldman | Neutral | $25 | -20.6% |
| Jun 26, 2025 | Initiated | Wells Fargo | Overweight | $44 | +39.7% |
Peers
Mkt cap| Ticker | Company | Mkt cap |
|---|---|---|
| IMCR | Immunocore Holdings plc ADR | 1.57B |
| TNGX | Tango Therapeutics Inc | 4.21B |
| AURA | Aura Biosciences Inc | 748.30M |
| REPL | Replimune Group Inc | 2.10B |
| RLAY | Relay Therapeutics Inc | 4.00B |
| ERAS | Erasca Inc | 5.52B |
| PBLS | Parabilis Medicines Inc | 3.32B |
| RVMD | Revolution Medicines Inc | 38.12B |
| CELC | Celcuity Inc | 3.14B |
| IOVA | Iovance Biotherapeutics Inc | 3.53B |
Insider trading
7 filings| Insider | Relationship | Date | Transaction | Cost | Shares | Value | Total held | Form |
|---|---|---|---|---|---|---|---|---|
| Hata Yujiro S | President and CEO | Oct 06 '26 | Option Exercise | 4.31 | 26,338 | 113,517 | 717,033 | Oct 08 07:03 PM |
| Hata Yujiro S | President and CEO | Oct 06 '26 | Sale | 37.41 | 26,338 | 985,397 | 690,695 | Oct 08 07:03 PM |
| YUJIRO HATA | CEO | Oct 06 '26 | Proposed Sale | 38.23 | 230,316 | 8,804,981 | Oct 06 04:13 PM | |
| Ruiz Briseno Andres | Chief Accounting Officer | Jul 07 '26 | Option Exercise | 12.86 | 9,550 | 122,813 | 36,016 | Jul 09 04:56 PM |
| Ruiz Briseno Andres | Chief Accounting Officer | Jul 07 '26 | Sale | 40.01 | 9,550 | 382,131 | 26,466 | Jul 09 04:56 PM |
| Andres Ruiz Briseno | Senior VP | Jul 07 '26 | Proposed Sale | 40.01 | 9,550 | 382,131 | Jul 07 04:54 PM | |
| Stein Jeffrey | Director | Mar 02 '26 | Buy | 32.96 | 50,000 | 1,647,890 | 54,281 | Mar 02 07:18 PM |
Held by
AUM| Ticker | Company | AUM |
|---|---|---|
| VTI | Vanguard Morningstar Total Stock Market ETF | AUM: 696.31B |
| IWM | iShares Russell 2000 Index Fund | AUM: 77.86B |
| XBI | State Street SPDR S&P Biotech ETF | AUM: 10.59B |
| VXF | Vanguard Extended Market Index ETF | AUM: 30.79B |
| IWN | iShares Russell 2000 Value ETF | AUM: 14.17B |
| IBB | iShares Biotechnology ETF | AUM: 11.39B |
| VTWO | Vanguard Russell 2000 Index ETF | AUM: 16.90B |
| DFAS | U.S. Small Cap Portfolio-ETF Class Shares | AUM: 15.64B |
| SCHA | Schwab U.S. Small-Cap ETF | AUM: 22.44B |
| DFAC | U.S. Core Equity 2 Portfolio-ETF Class Shares | AUM: 49.67B |
News
latest 14 of 200- IDEAYA Biosciences to Participate in Upcoming November 2026 Investor Relations Events (PR Newswire)
- IDEAYA Biosciences Reports Financial Results for the Third Quarter 2026 and Provides a Business Update (PR Newswire)
- IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
- IDE849 (SHR-4849) DLL3 TOP1 ADC Updated Phase 1 Results at ESMO 2026 Demonstrates Promising Anti-Tumor Activity and Preliminary Overall Survival Results in Relapsed Small Cell Lung Cancer and Neuroendocrine Carcinomas (PR Newswire)
- IDEAYA Biosciences and Servier Announce Data From Three Clinical Trials at ESMO 2026 Supporting the Potential of Darovasertib to Become a Foundational New Therapy for Patients Across the Treatment Journey of Uveal Melanoma (PR Newswire)
- IDEAYA Biosciences Announces the Promotion of Dr. Michael White to President, Research and Development (PR Newswire)
- IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
- IDEAYA Biosciences and Servier Announce First Patient Dosed in OptimUM-11 Global Phase 3 Registrational Trial of Darovasertib and Crizotinib as Adjuvant Therapy for Subjects with Uveal Melanoma (PR Newswire)
- IDEAYA Biosciences Announces London Investor R&D Day and Participation in Upcoming September 2026 Investor Conferences (PR Newswire)
- IDEAYA Biosciences Announces Successful FDA Type C Meeting for IDE849, DLL3 TOP1 ADC, on Phase 3 Registrational Trial Design for Potential Accelerated and Full Approval in Extensive Stage Small Cell Lung Cancer (PR Newswire)
- IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
- IDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer (PR Newswire)
- IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update (PR Newswire)
- IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Quarterly earnings
2026Q3 EPS -1.220 missed -1.180, from 1.466 a year earlier. Sales 10.24 beat 7.58, from 207.83 a year earlier
The outline behind the bar is the estimate. The filled bar is the print. Green beat it, red missed it.
| Period | Reported | EPS adjusted | EPS est | EPS reported | Sales act, USD m | Sales est, USD m | Surprise | Year-ago quarter | Analysts | Next session |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026Q3ended 2026-09-30 | 2026-11-03 08:30 | -1.220 | -1.180 | -1.220 | 10.24 | 7.58 | EPS +3.4% · sales +35.1% | vs 2025Q3, year-ago quarter · EPS -183.2% · sales -95.1% | 15 | Open -0.19% vs SPY +0.08%. Close -0.98% vs SPY +0.30% |
| 2026Q2ended 2026-06-30 | 2026-08-04 08:30 | -1.220 | -1.057 | -1.222 | 8.86 | 8.02 | EPS +15.5% · sales +10.4% | vs 2025Q2, year-ago quarter · EPS +38.6% · sales - | 14 EPS · 13 sales | Open +2.53% vs SPY +0.39%. Close +2.01% vs SPY +1.80% |
| 2026Q1ended 2026-03-31 | 2026-05-05 08:30 | -1.110 | -0.989 | -1.111 | 6.56 | 5.04 | EPS +12.3% · sales +30.2% | vs 2025Q1, year-ago quarter · EPS +35.4% · sales - | 16 | Open -2.70% vs SPY +0.52%. Close -0.35% vs SPY +0.80% |
| 2025Q4ended 2025-12-31 | 2026-02-17 08:30 | -0.940 | -0.952 | -0.940 | 10.88 | 6.31 | EPS -1.2% · sales +72.5% | vs 2024Q4, year-ago quarter · EPS -36.9% · sales +55.4% | 18 EPS · 16 sales | Open -1.09% vs SPY -0.24%. Close +1.62% vs SPY +0.16% |
| 2025Q3ended 2025-09-30 | 2025-11-04 08:30 | 1.466 | -0.827 | 1.330 | 207.83 | 6.34 | EPS -277.4% · sales +3179.0% | vs 2024Q3, year-ago quarter · EPS -344.3% · sales - | 14 EPS · 11 sales | Open -1.85% vs SPY -1.06%. Close -2.81% vs SPY -1.19% |
| 2025Q2ended 2025-06-30 | 2025-08-05 08:30 | -0.880 | -0.782 | -0.876 | 0.00 | 4.19 | EPS +12.6% · sales -100.0% | vs 2024Q2, year-ago quarter · EPS +29.4% · sales - | 14 EPS · 13 sales | Open +0.24% vs SPY +0.10%. Close -3.52% vs SPY -0.51% |
| 2025Q1ended 2025-03-31 | 2025-05-06 08:30 | -0.820 | -0.661 | -0.817 | 0.00 | 2.15 | EPS +24.0% · sales -100.0% | vs 2024Q1, year-ago quarter · EPS +54.7% · sales - | 9 EPS · 7 sales | Open +0.10% vs SPY -0.99%. Close -13.29% vs SPY -0.84% |
| 2024Q4ended 2024-12-31 | 2025-02-13 08:30 | -1.490 | -0.629 | -1.492 | 7.00 | 5.09 | EPS +137.0% · sales +37.5% | vs 2023Q4, year-ago quarter · EPS +186.5% · sales +78.4% | 13 EPS · 11 sales | Open -2.78% vs SPY +0.19%. Close -5.42% vs SPY +1.06% |
| 2024Q3ended 2024-09-30 | 2024-11-04 08:30 | -0.600 | -0.648 | -0.601 | 0.00 | 4.27 | EPS -7.4% · sales -100.0% | vs 2023Q3, year-ago quarter · EPS +30.4% · sales -100.0% | 12 | Open +0.80% vs SPY +0.02%. Close +4.90% vs SPY -0.22% |
| 2024Q2ended 2024-06-30 | 2024-08-06 08:30 | -0.680 | -0.536 | -0.677 | 0.00 | 4.46 | EPS +27.0% · sales -100.0% | vs 2023Q2, year-ago quarter · EPS +36.0% · sales -100.0% | 12 | Open -2.38% vs SPY +0.36%. Close -2.68% vs SPY +0.92% |
| 2024Q1ended 2024-03-31 | 2024-05-07 08:30 | -0.530 | -0.510 | -0.527 | 0.00 | 5.43 | EPS +4.0% · sales -100.0% | vs 2023Q1, year-ago quarter · EPS +8.2% · sales -100.0% | 11 EPS · 9 sales | Open -1.49% vs SPY +0.19%. Close -0.79% vs SPY +0.11% |
| 2023Q4ended 2023-12-31 | 2024-02-20 08:30 | -0.520 | -0.468 | -0.520 | 3.92 | 8.84 | EPS +11.2% · sales -55.6% | vs 2022Q4, year-ago quarter · EPS +4.0% · sales -2.5% | 10 | Open -1.08% vs SPY -0.36%. Close -6.62% vs SPY -0.55% |
| 2023Q3ended 2023-09-30 | 2023-11-07 08:30 | -0.460 | -0.489 | -0.457 | 8.04 | 8.38 | EPS -5.9% · sales -4.1% | vs 2022Q3, year-ago quarter · EPS -1250.0% · sales -72.9% | 11 EPS · 10 sales | - |
| 2023Q2ended 2023-06-30 | 2023-08-10 08:30 | -0.500 | -0.552 | -0.496 | 3.54 | 4.89 | EPS -9.4% · sales -27.5% | vs 2022Q2, year-ago quarter · EPS -12.3% · sales -39.4% | 11 EPS · 9 sales | - |
| 2023Q1ended 2023-03-31 | 2023-05-09 08:30 | -0.490 | -0.541 | -0.489 | 7.88 | 6.14 | EPS -9.5% · sales +28.3% | vs 2022Q1, year-ago quarter · EPS +36.1% · sales -30.6% | 9 EPS · 7 sales | - |
| 2022Q4ended 2022-12-31 | 2023-03-07 08:30 | -0.500 | -0.555 | -0.503 | 4.02 | 7.00 | EPS -9.9% · sales -42.5% | vs 2021Q4, year-ago quarter · EPS +6.4% · sales +35.7% | 9 EPS · 8 sales | - |
Annual earnings
2025FY EPS -1.280 beat -1.287, from -3.360 a year earlier. Sales 218.71 beat 216.88, from 7.00 a year earlier
Reported years only. The outline behind the bar is the estimate. A later year with no print stays in the table.
earnings feed, not the snapshot. Not the statement ratio.
| Period | EPS adjusted | EPS est | EPS reported | Sales act, USD m | Sales est, USD m | P/E, earnings feed |
|---|---|---|---|---|---|---|
| 2030FYestimate | - | 0.025 | - | - | 891.44 | 1259.60 |
| 2029FYestimate | - | -2.055 | - | - | 538.49 | - |
| 2028FYestimate | - | -3.511 | - | - | 270.35 | - |
| 2027FYestimate | - | -4.361 | - | - | 124.45 | - |
| 2026FYestimate | - | -4.723 | - | - | 45.37 | - |
| 2025FY | -1.280 | -1.287 | -1.280 | 218.71 | 216.88 | - |
| 2024FY | -3.360 | -2.467 | -3.361 | 7.00 | 4.67 | - |
| 2023FY | -1.960 | -1.907 | -1.964 | 23.39 | 28.28 | - |
| 2022FY | -1.420 | -1.434 | -1.415 | 50.93 | 53.92 | - |
| 2021FY | -1.410 | -1.228 | -1.412 | 27.94 | 33.97 | - |
| 2020FY | -1.400 | -1.427 | -1.395 | 19.54 | 16.91 | - |
| 2019FY | -3.360 | -2.576 | -3.359 | 0.00 | 0.00 | - |
Quarterly results
2026Q3 revenue 10.24, from 207.83 a year earlier. Operating margin -1,344%, from 52.2% a year earlier
From the quarterly statement. Not an estimate.
Estimate revisions
Latest snapshot of each period and type. 2026FY E -4.72 per share.
| Period | Type | Scale | Date | Mean | vs prior date |
|---|---|---|---|---|---|
| 2026FY | E | per share | 2026-11-09 | -4.72 | +0.0% |
| 2026Q4 | E | per share | 2026-11-09 | -1.17 | 0.0% |
| 2026Q4 | S | per share | 2026-11-09 | 18.85 | +0.0% |
| 2026FY | S | per share | 2026-11-06 | 45.37 | +0.4% |
| 2026FY | R | per share | 2026-11-03 | -4.77 | +0.6% |
| 2026Q4 | R | per share | 2026-11-03 | -1.18 | +4.4% |
| 2026Q3 | E | per share | 2026-11-01 | -1.18 | 0.0% |
| 2026Q3 | S | per share | 2026-10-28 | 7.58 | 0.0% |
| 2026Q3 | R | per share | 2026-10-21 | -1.28 | 0.0% |
| 2026Q2 | E | per share | 2026-07-30 | -1.06 | -0.4% |
| 2026Q2 | S | per share | 2026-07-21 | 8.02 | +0.5% |
| 2026Q2 | R | per share | 2026-07-19 | -1.18 | 0.0% |
| 2026Q1 | E | per share | 2026-05-04 | -0.99 | 0.0% |
| 2026Q1 | R | per share | 2026-05-04 | -1.05 | 0.0% |
| 2026Q1 | S | per share | 2026-05-03 | 5.04 | 0.0% |
| 2025Q4 | S | per share | 2026-01-30 | 6.31 | +6.3% |
| 2025FY | S | - | 2026-01-26 | 216.88 | +0.0% |
| 2025FY | E | per share | 2026-01-24 | -1.29 | 0.0% |
| 2025Q4 | E | per share | 2026-01-24 | -0.95 | 0.0% |
| 2025Q4 | R | per share | 2026-01-19 | -1.05 | 0.0% |
| 2025FY | R | per share | 2026-01-18 | -1.32 | 0.0% |
| 2025Q3 | E | per share | 2025-10-28 | -0.83 | 0.0% |
| 2025Q3 | R | per share | 2025-10-19 | -0.88 | 0.0% |
| 2025Q3 | S | per share | 2025-10-19 | 6.34 | 0.0% |
| 2025Q2 | E | per share | 2025-08-04 | -0.78 | 0.0% |
| 2025Q2 | R | per share | 2025-08-04 | -0.82 | 0.0% |
| 2025Q2 | S | per share | 2025-07-28 | 4.19 | +8.2% |
| 2025Q1 | E | per share | 2025-05-05 | -0.66 | 0.0% |
| 2025Q1 | S | per share | 2025-04-29 | 2.15 | 0.0% |
| 2025Q1 | R | per share | 2025-03-31 | -0.65 | -6.9% |
| 2024FY | E | per share | 2025-01-22 | -2.47 | 0.0% |
| 2024Q4 | E | per share | 2025-01-22 | -0.63 | 0.0% |
| 2024FY | S | per share | 2025-01-22 | 4.67 | 0.0% |
| 2024Q4 | S | per share | 2025-01-22 | 5.09 | 0.0% |
| 2024FY | R | per share | 2025-01-20 | -2.48 | 0.0% |
| 2024Q4 | R | per share | 2025-01-20 | -0.64 | 0.0% |
| 2024Q3 | E | per share | 2024-10-31 | -0.63 | +0.4% |
| 2024Q3 | S | per share | 2024-10-31 | 4.27 | -1.3% |
| 2024Q3 | R | per share | 2024-10-23 | -0.66 | -6.7% |
| 2024Q2 | E | per share | 2024-07-30 | -0.54 | 0.0% |
| 2024Q2 | S | per share | 2024-07-26 | 4.46 | -8.3% |
| 2024Q2 | R | per share | 2024-07-21 | -0.54 | 0.0% |
| 2024Q1 | E | per share | 2024-05-06 | -0.51 | 0.0% |
| 2024Q1 | S | per share | 2024-05-06 | 5.43 | 0.0% |
| 2024Q1 | R | per share | 2024-05-05 | -0.53 | 0.0% |
| 2023FY | E | per share | 2024-02-17 | -1.91 | 0.0% |
| 2023FY | S | per share | 2024-02-17 | 28.28 | 0.0% |
| 2023FY | R | per share | 2024-01-21 | -2.06 | 0.0% |
Estimate history
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | MRQ |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS per share | -0.586 | -1.698 | -3.359 | -1.395 | -1.412 | -1.415 | -1.964 | -3.361 | -1.285 | -4.494 | - |
| Sales USD millions | 0 | 0 | 0 | 20 | 28 | 51 | 23 | 7 | 219 | 37 | - |
| Shares million shares | 20 | 20 | 20 | 30 | 39 | 48 | 65 | 87 | 88 | - | 97 |
| Metric | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|---|
| EPS per share | -0.601 | -1.492 | -0.817 | -0.876 | 1.33 | -0.94 | -1.111 | -1.222 | -1.222 |
| Sales USD millions | 0 | 7 | 0 | 0 | 208 | 11 | 7 | 9 | 10 |
| Shares million shares | 86 | 87 | 88 | 88 | 88 | 88 | 88 | 96 | 97 |
Income statement, annual
| Metric | TTM | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 | 2018FY12/31/2018 |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 36.53 | 218.71+3024.4% | 7.00-70.1% | 23.39-54.1% | 50.93+82.3% | 27.94+43.0% | 19.54 | 0.00 | 0.00 |
| Cost of Goods Sold Incl. D&A | 4.50 | 4.59+19.8% | 3.83-4.5% | 4.01+91.0% | 2.10+21.4% | 1.73+25.4% | 1.38+10.4% | 1.25+40.4% | 0.89 |
| Gross Profit | 32.03 | 214.12+6654.6% | 3.17-83.6% | 19.38-60.3% | 48.83+86.2% | 26.22+44.4% | 18.16 | -1.25 | -0.89 |
| Selling, General and Administrative Excl. Other | 495.07 | 373.43+13.1% | 330.14+114.6% | 153.81+38.2% | 111.33+45.6% | 76.48+43.0% | 53.50+24.3% | 43.03+21.1% | 35.53 |
| Research and Development | 412.59 | 314.70+6.8% | 294.67+127.5% | 129.51+44.6% | 89.54+54.0% | 58.16+46.5% | 39.70+15.7% | 34.32+8.1% | 31.75 |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -463.04 | -159.31 | -326.98 | -134.43 | -62.50 | -50.27 | -35.34 | -44.27 | -36.42 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Unusual Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | 0.00 |
| Net Income Before Taxes | -420.01 | -113.70 | -274.48 | -112.96 | -58.66 | -49.76 | -34.49 | -41.98 | -34.35 |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consolidated Net Income | -420.01 | -113.70 | -274.48 | -112.96 | -58.66 | -49.76 | -34.49 | -41.98 | -34.35 |
| Net Income From Continuing Operations | -420.01 | -113.70 | -274.48 | -112.96 | -58.66 | -49.76 | -34.49 | -41.98 | -34.35 |
| Net Income | -420.01 | -113.70 | -274.48 | -112.96 | -58.66 | -49.76 | -34.49 | -41.98 | -34.35 |
| EPS (Recurring) per share | -4.08 | -1.28 | -3.36 | -1.96 | -1.42 | -1.41 | -1.40 | -3.36 | -1.70 |
| EPS (Basic, Before Extraordinaries) per share | -4.49 | -1.28 | -3.36 | -1.96 | -1.42 | -1.41 | -1.40 | -3.36 | -1.70 |
| EPS (Diluted) per share | -4.49 | -1.28 | -3.36 | -1.96 | -1.42 | -1.41 | -1.40 | -3.36 | -1.70 |
| EBITDA | -458.53 | -154.72 | -323.14 | -130.42 | -60.40 | -48.54 | -33.96 | -43.03 | -35.53 |
| Non-Operating Income (Expense) | 43.02 | 45.62-13.1% | 52.50+144.5% | 21.47+457.7% | 3.85+654.9% | 0.51-40.0% | 0.85-63.0% | 2.30+11.1% | 2.07 |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 60.72 | 46.12+32.7% | 34.75+87.9% | 18.49+59.0% | 11.63+41.1% | 8.24+128.3% | 3.61+66.4% | 2.17+189.3% | 0.75 |
| Price To Sales Ratio ratio | 108.26 | 13.99 | 299.88 | 87.52 | 14.79 | 29.83 | 17.71 | - | - |
| Gross Margin % | 87.67 | 97.90 | 45.23 | 82.86 | 95.87 | 93.83 | 92.93 | - | - |
| Operating Margin % | -1,267.38 | -72.84 | -4,671.07 | -574.85 | -122.72 | -179.91 | -180.90 | - | - |
| Net Margin % | -1,149.62 | -51.99 | -3,921.10 | -483.05 | -115.17 | -178.10 | -176.55 | - | - |
| Shares Outstanding million shares | 96.65 | 87.80+1.5% | 86.50+33.0% | 65.04+35.0% | 48.19+25.1% | 38.53+30.4% | 29.54+45.2% | 20.34+0.1% | 20.31 |
| Market Capitalization | 3,044.91 | 3,044.91+37.1% | 2,221.30-3.1% | 2,293.47+162.3% | 874.22-3.9% | 910.08+123.6% | 406.98+166.9% | 152.48-4.9% | 160.41 |
Income statement, quarterly
| Metric | 2026Q39/30/2026 | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 10.24-95.1% | 8.86 | 6.56 | 10.88+55.4% | 207.83 | 0.00 | 0.00 | 7.00+78.6% |
| Cost of Goods Sold Incl. D&A | 1.030.0% | 1.13-8.1% | 1.14+0.9% | 1.20+87.5% | 1.03+2.0% | 1.23+11.8% | 1.13+4.6% | 0.64-37.3% |
| Gross Profit | 9.21-95.5% | 7.72 | 5.42 | 9.68+52.2% | 206.80 | -1.23 | -1.13 | 6.36+119.3% |
| Selling, General and Administrative Excl. Other | 146.84+49.3% | 130.01+48.5% | 113.96+36.9% | 104.25-30.7% | 98.35+49.3% | 87.57+37.2% | 83.26+66.7% | 150.50+235.9% |
| Research and Development | 121.58+46.5% | 108.69+46.4% | 95.73+35.0% | 86.60-38.2% | 82.99+45.2% | 74.23+36.1% | 70.89+65.6% | 140.18+261.6% |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -137.63-226.9% | -122.29 | -108.54 | -94.57 | 108.45 | -88.81 | -84.39 | -144.14 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Unusual Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Before Taxes | -125.75-205.5% | -112.45 | -98.54 | -83.27 | 119.24 | -77.49 | -72.18 | -130.31 |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consolidated Net Income | -125.75-205.5% | -112.45 | -98.54 | -83.27 | 119.24 | -77.49 | -72.18 | -130.31 |
| Net Income From Continuing Operations | -125.75-205.5% | -112.45 | -98.54 | -83.27 | 119.24 | -77.49 | -72.18 | -130.31 |
| Net Income | -125.75-205.5% | -112.45 | -98.54 | -83.27 | 119.24 | -77.49 | -72.18 | -130.31 |
| EPS (Recurring) per share | -1.22-191.7% | -1.22 | -1.11 | -0.94 | 1.33 | -0.88 | -0.82 | -1.49 |
| EPS (Basic, Before Extraordinaries) per share | -1.22-190.4% | -1.22 | -1.11 | -0.94 | 1.35 | -0.88 | -0.82 | -1.49 |
| EPS (Diluted) per share | -1.22-191.7% | -1.22 | -1.11 | -0.94 | 1.33 | -0.88 | -0.82 | -1.49 |
| EBITDA | -136.60-224.8% | -121.16 | -107.40 | -93.37 | 109.48 | -87.57 | -83.26 | -143.50 |
| Non-Operating Income (Expense) | 11.88+10.1% | 9.84-13.0% | 10.01-18.0% | 11.30-18.3% | 10.79-28.4% | 11.31-6.9% | 12.21+6.6% | 13.83+73.7% |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 17.73+45.1% | 16.66+40.4% | 14.54+42.0% | 11.79+24.4% | 12.22+32.7% | 11.87+22.0% | 10.24+62.3% | 9.48+97.5% |
| Price To Sales Ratio ratio | 108.26 | 14.65 | 13.12 | 14.00 | 11.36 | 265.67 | 206.75 | 320.67 |
| Gross Margin % | 89.93 | 87.21 | 82.58 | 88.99 | 99.50 | - | - | 90.81 |
| Operating Margin % | -1,343.80 | -1,380.73 | -1,654.63 | -869.53 | 52.18 | - | - | -2,059.11 |
| Net Margin % | -1,227.78 | -1,269.64 | -1,502.12 | -765.66 | 57.37 | - | - | -1,861.60 |
| Shares Outstanding million shares | 96.65+10.2% | 96.38+10.0% | 87.86+0.3% | 87.80+1.5% | 87.67+1.5% | 87.64+15.2% | 87.57+17.1% | 86.50+33.0% |
| Market Capitalization | 3,044.91+27.7% | 3,543.75+92.5% | 2,925.96+104.1% | 3,030.63+36.4% | 2,384.79-10.9% | 1,840.97-30.7% | 1,433.86-56.2% | 2,221.30-3.1% |
Balance sheet, annual
| Metric | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 | 2018FY12/31/2018 | 2017FY12/31/2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 639.39-5.5% | 676.32+28.8% | 525.11+43.9% | 364.83+47.8% | 246.77-13.0% | 283.58+186.6% | 98.96+10.0% | 89.96+583.6% | 13.16 |
| Short Term Receivables | 5.97 | 0.00-100.0% | 0.02-90.5% | 0.21-80.9% | 1.10-41.5% | 1.88 | 0.00 | 0.00 | 0.00 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 21.37+59.6% | 13.39+78.5% | 7.50+38.6% | 5.41+73.4% | 3.12-0.6% | 3.14+16.3% | 2.70+280.3% | 0.71+69.0% | 0.42 |
| Total Current Assets | 666.73-3.3% | 689.71+29.5% | 532.63+43.8% | 370.45+47.6% | 251.00-13.0% | 288.61+183.9% | 101.65+12.1% | 90.67+567.7% | 13.58 |
| Net Property, Plant & Equipment | 31.29+12.8% | 27.74+229.8% | 8.41-6.5% | 8.99+3.8% | 8.66-8.6% | 9.48-2.3% | 9.70+88.3% | 5.15+37.7% | 3.74 |
| Total Investments and Advances | 411.31+1.1% | 406.64+275.6% | 108.25+1185.6% | 8.42-93.1% | 121.40+110263.6% | 0.11-93.3% | 1.63+1381.8% | 0.11+57.1% | 0.07 |
| Intangible Assets | 0.00 | 0.00 | - | - | - | - | 0.00 | 0.00 | 0.00 |
| Other Assets | 0.00 | 0.00-100.0% | 0.03-70.0% | 0.10-65.5% | 0.29+262.5% | 0.08+300.0% | 0.02-96.8% | 0.62+588.9% | 0.09 |
| Total Assets | 1,109.32-1.3% | 1,124.09+73.1% | 649.32+67.4% | 387.97+1.7% | 381.35+27.9% | 298.27+164.0% | 113.00+17.0% | 96.54+452.3% | 17.48 |
| Short Term Debt Incl. Current Port. of LT Debt | 0.34+13.3% | 0.30-82.9% | 1.75-6.4% | 1.87+10.0% | 1.70+10.4% | 1.54+33.9% | 1.15 | 0.00 | 0.00 |
| Accounts Payable | 17.58+14.0% | 15.42+133.6% | 6.60+54.2% | 4.28+103.8% | 2.10+121.1% | 0.95+33.8% | 0.71-50.0% | 1.42+115.2% | 0.66 |
| Other Current Liabilities | 40.89+34.7% | 30.35+61.8% | 18.76-26.6% | 25.57-38.2% | 41.36+14.4% | 36.15+610.2% | 5.09+27.2% | 4.00+126.0% | 1.77 |
| Total Current Liabilities | 58.81+27.7% | 46.07+70.0% | 27.10-14.6% | 31.72-29.8% | 45.16+16.9% | 38.64+456.8% | 6.94+28.3% | 5.41+122.6% | 2.43 |
| Long Term Debt | 27.57+46.1% | 18.87+1584.8% | 1.12-30.4% | 1.61-53.7% | 3.48-32.8% | 5.18-8.0% | 5.63 | 0.00-100.0% | 3.21 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 0.00 | 0.00 | 0.00-100.0% | 5.18-83.4% | 31.19-44.5% | 56.17+187133.3% | 0.03-98.2% | 1.69+13.4% | 1.49 |
| Total Liabilities | 86.39+33.0% | 64.94+130.0% | 28.23-26.7% | 38.51-51.8% | 79.83-20.2% | 100.00+693.7% | 12.60+77.5% | 7.10-0.4% | 7.13 |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 138.39+430.6% | 26.08 |
| Common Equity | 1,022.93-3.4% | 1,059.15+70.5% | 621.09+77.7% | 349.45+15.9% | 301.51+52.1% | 198.27+97.5% | 100.40 | -48.95 | -15.74 |
| Total Shareholders Equity | 1,022.93-3.4% | 1,059.15+70.5% | 621.09+77.7% | 349.45+15.9% | 301.51+52.1% | 198.27+97.5% | 100.40+12.3% | 89.44+764.2% | 10.35 |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 1,022.93-3.4% | 1,059.15+70.5% | 621.09+77.7% | 349.45+15.9% | 301.51+52.1% | 198.27+97.5% | 100.40+12.3% | 89.44+764.2% | 10.35 |
| Total Liabilities & Stockholders Equity | 1,109.32-1.3% | 1,124.09+73.1% | 649.32+67.4% | 387.97+1.7% | 381.35+27.9% | 298.27+164.0% | 113.00+17.0% | 96.54+452.3% | 17.48 |
| Book Value Per Share per share | 11.65-4.8% | 12.24+28.2% | 9.55+31.7% | 7.25-7.3% | 7.82+16.5% | 6.71+35.8% | 4.94 | -2.41 | -0.78 |
| Tangible Book Value Per Share per share | 11.65-4.8% | 12.24+28.2% | 9.55+31.7% | 7.25-7.3% | 7.82+16.5% | 6.71+35.8% | 4.94 | -2.41 | -0.78 |
| Full-Time Employees people | 145+10.7% | 131+5.6% | 124+20.4% | 103+27.2% | 81+30.6% | 62+31.9% | 47-19.0% | 58 | - |
| Price to Book Ratio ratio | 2.79 | 1.88 | 4.11 | 2.37 | 3.02 | 2.09 | 1.52 | 1.45 | - |
| Return on Assets % | -10.18 | -30.95 | -21.78 | -15.25 | -14.64 | -16.77 | -40.06 | -60.25 | - |
| Return on Equity % | -10.92 | -32.67 | -23.28 | -18.02 | -19.91 | -23.10 | -44.22 | -68.84 | - |
| Return on Invested Capital % | -10.82 | -25.46 | -18.15 | -16.71 | -16.32 | -16.95 | -39.59 | -38.40 | -87.53 |
| Quick Ratio ratio | 11.34 | 14.97 | 19.65 | 11.68 | 5.56 | 7.47 | 14.65 | 16.75 | 5.58 |
| Current Ratio ratio | 11.34 | 14.97 | 19.65 | 11.68 | 5.56 | 7.47 | 14.65 | 16.75 | 5.58 |
Cash flow, annual
| Metric | TTM | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 | 2018FY12/31/2018 |
|---|---|---|---|---|---|---|---|---|---|
| Net Income | -420.01 | -113.70 | -274.48 | -112.96 | -58.66 | -49.76 | -34.49 | -41.98 | -34.35 |
| Depreciation | 4.49 | 4.59+19.8% | 3.83-4.5% | 4.01+91.0% | 2.10+21.4% | 1.73+25.4% | 1.38+10.4% | 1.25+40.4% | 0.89 |
| Other Funds (Non Cash) | 55.75 | 36.14+214.0% | 11.51+65.9% | 6.94-36.5% | 10.93+8.5% | 10.07+141.5% | 4.17+145.3% | 1.70-59.4% | 4.19 |
| Funds from Operations | -359.77 | -72.97 | -259.13 | -102.02 | -45.62 | -37.97 | -28.94 | -39.03 | -29.27 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | 12.41 | 1.87-83.8% | 11.55 | -13.21 | -41.55 | -17.81-121.1% | 84.41 | -0.28-117.0% | 1.65 |
| Cash from Operating Activities | -347.36 | -71.10 | -247.58 | -115.22 | -87.17 | -55.78-200.6% | 55.46 | -39.31 | -27.62 |
| Capital Expenditures | -2.44 | -2.37 | -3.86 | -2.37 | -3.44 | -2.64 | -0.49 | -1.35 | -1.71 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Purchase or Sale of Investments | -53.42 | 72.34 | -498.70 | -156.09 | -29.96 | -67.02 | -145.75-4126.2% | 3.62 | -61.47 |
| Purchase of Investments | -655.55 | -607.89 | -1,191.31 | -595.98 | -255.81 | -315.00 | -242.31 | -88.00 | -133.30 |
| Sale Or Maturity of Investments | 602.13 | 680.23-1.8% | 692.61+57.5% | 439.89+94.8% | 225.85-8.9% | 247.97+156.8% | 96.56+5.4% | 91.62+27.6% | 71.83 |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | -55.86 | 69.98 | -502.56 | -158.46 | -33.40 | -69.67 | -146.24-6542.3% | 2.27 | -63.18 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 366.22 | 29.78-95.6% | 677.55+86.8% | 362.72+273.3% | 97.17-33.2% | 145.45+13.0% | 128.75+154.4% | 50.61-52.0% | 105.38 |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 366.22 | 29.78-95.6% | 677.55+86.8% | 362.72+273.3% | 97.17-33.2% | 145.45+13.0% | 128.75+154.4% | 50.61-52.0% | 105.38 |
| Proceedsfrom Stock Options | 357.79 | 26.35-96.0% | 665.07+88.3% | 353.16+269.0% | 95.72-33.5% | 143.95+12.8% | 127.56+153.5% | 50.32-52.2% | 105.29 |
| Issuance or Reduction of Debt, Net | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Activities Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Financing Activities | 366.22 | 29.78-95.6% | 677.55+86.8% | 362.72+273.3% | 97.17-33.2% | 145.45+13.0% | 128.75+154.4% | 50.61-52.0% | 105.38 |
| Net Change in Cash | -37.00 | 28.66 | -72.59-181.5% | 89.04 | -23.41-217.0% | 20.01-47.3% | 37.97+180.0% | 13.56-7.0% | 14.58 |
| Free Cash Flow | -349.80 | -73.47 | -251.44 | -117.59 | -90.62 | -58.42-206.3% | 54.97 | -40.67 | -29.33 |
| Preferred Dividends (Cash Flow) | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price to Free Cash Flow ratio | - | - | - | - | - | - | 6.30 | - | - |
| Deferred Taxes & Investment Tax Credit | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Balance sheet, quarterly
| Metric | 2026Q39/30/2026 | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 838.54+6.6% | 828.96+23.8% | 671.20-3.1% | 639.39-5.5% | 786.89-14.5% | 669.74-4.5% | 692.51-0.9% | 676.32+28.8% |
| Short Term Receivables | 10.24 | 15.42 | 6.56 | 5.97 | 0.00-100.0% | 0.00 | 0.00-100.0% | 0.00-100.0% |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 23.18+47.1% | 19.65+23.9% | 18.35+19.5% | 21.37+59.6% | 15.76+29.6% | 15.86+37.7% | 15.36+45.3% | 13.39+78.5% |
| Total Current Assets | 871.97+8.6% | 864.02+26.0% | 696.11-1.7% | 666.73-3.3% | 802.65-13.9% | 685.60-3.9% | 707.87-0.2% | 689.71+29.5% |
| Net Property, Plant & Equipment | 29.58-6.7% | 30.46-6.9% | 31.25-6.2% | 31.29+12.8% | 31.72+19.2% | 32.73+288.3% | 33.30+283.2% | 27.74+229.8% |
| Total Investments and Advances | 313.57-10.6% | 415.21+28.6% | 302.99-15.7% | 411.31+1.1% | 350.76+24.8% | 322.94+28.2% | 359.47+47.7% | 406.64+275.6% |
| Intangible Assets | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 0.91 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 0.00-100.0% | 0.00-100.0% |
| Total Assets | 1,216.02+2.6% | 1,309.70+25.8% | 1,030.35-6.4% | 1,109.32-1.3% | 1,185.14-4.4% | 1,041.27+6.9% | 1,100.64+14.5% | 1,124.09+73.1% |
| Short Term Debt Incl. Current Port. of LT Debt | 2.15+551.5% | 1.19+271.9% | 0.35+12.9% | 0.34+13.3% | 0.33 | 0.32-47.5% | 0.31-73.0% | 0.30-82.9% |
| Accounts Payable | 22.04+19.6% | 30.51+76.7% | 20.74+17.6% | 17.58+14.0% | 18.43+46.6% | 17.27+8.7% | 17.63+180.3% | 15.42+133.6% |
| Other Current Liabilities | 72.22+57.9% | 50.98+35.0% | 43.74+32.9% | 40.89+34.7% | 45.75+62.9% | 37.75+55.7% | 32.91+87.8% | 30.35+61.8% |
| Total Current Liabilities | 96.41+49.4% | 82.68+49.4% | 64.83+27.5% | 58.81+27.7% | 64.51+58.7% | 55.34+35.8% | 50.85+103.7% | 46.07+70.0% |
| Long Term Debt | 27.55+2.3% | 28.12+7.0% | 28.25+10.1% | 27.57+46.1% | 26.92+43.2% | 26.28+1985.7% | 25.66+1936.5% | 18.87+1584.8% |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 0.00-100.0% | 0.00 | 0.00 | 0.00 | 1.68 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 123.96+33.1% | 110.79+35.7% | 93.08+21.7% | 86.39+33.0% | 93.10+56.6% | 81.62+94.3% | 76.51+191.8% | 64.94+130.0% |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | 1,092.06+0.0% | 1,198.90+24.9% | 937.27-8.5% | 1,022.93-3.4% | 1,092.03-7.5% | 959.65+3.0% | 1,024.13+9.5% | 1,059.15+70.5% |
| Total Shareholders Equity | 1,092.06+0.0% | 1,198.90+24.9% | 937.27-8.5% | 1,022.93-3.4% | 1,092.03-7.5% | 959.65+3.0% | 1,024.13+9.5% | 1,059.15+70.5% |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 1,092.06+0.0% | 1,198.90+24.9% | 937.27-8.5% | 1,022.93-3.4% | 1,092.03-7.5% | 959.65+3.0% | 1,024.13+9.5% | 1,059.15+70.5% |
| Total Liabilities & Stockholders Equity | 1,216.02+2.6% | 1,309.70+25.8% | 1,030.35-6.4% | 1,109.32-1.3% | 1,185.14-4.4% | 1,041.27+6.9% | 1,100.64+14.5% | 1,124.09+73.1% |
| Book Value Per Share per share | 11.30-9.3% | 12.44+13.6% | 10.67-8.8% | 11.65-4.8% | 12.46-8.9% | 10.95-10.5% | 11.70-6.5% | 12.24+28.2% |
| Tangible Book Value Per Share per share | 11.30-9.3% | 12.44+13.6% | 10.67-8.8% | 11.65-4.8% | 12.46-8.9% | 10.95-10.5% | 11.70-6.5% | 12.24+28.2% |
| Full-Time Employees people | - | - | - | 145+10.7% | - | - | - | 131+5.6% |
| Price to Book Ratio ratio | 2.79 | 3.49 | 2.86 | 2.78 | 2.48 | 1.80 | 1.34 | 1.88 |
| Return on Assets % | -34.98 | -14.89 | -13.14 | -10.18 | -13.26 | -32.93 | -29.78 | -30.95 |
| Return on Equity % | -38.46 | -16.22 | -14.28 | -10.92 | -14.15 | -35.09 | -31.34 | -32.67 |
| Return on Invested Capital % | -11.23 | -9.16 | -10.21 | -7.93 | 10.66 | -7.86 | -6.88 | -12.09 |
| Quick Ratio ratio | 9.04 | 10.45 | 10.74 | 11.34 | 12.44 | 12.39 | 13.92 | 14.97 |
| Current Ratio ratio | 9.04 | 10.45 | 10.74 | 11.34 | 12.44 | 12.39 | 13.92 | 14.97 |
Cash flow, quarterly
| Metric | 2026Q39/30/2026 | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -125.75-205.5% | -112.45 | -98.54 | -83.27 | 119.24 | -77.49 | -72.18 | -130.31 |
| Depreciation | 1.030.0% | 1.12-8.9% | 1.14+0.9% | 1.20+87.5% | 1.03+2.0% | 1.23+11.8% | 1.13+4.6% | 0.64-37.3% |
| Other Funds (Non Cash) | 16.52+61.5% | 15.64+70.4% | 13.32+106.2% | 10.27+124.7% | 10.23+165.7% | 9.18+197.1% | 6.46 | 4.57+396.7% |
| Funds from Operations | -108.20-182.9% | -95.69 | -84.07 | -71.81 | 130.51 | -67.08 | -64.59 | -125.10 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | 14.72+25.7% | 7.48+62.3% | 8.90+109.9% | -18.69-643.3% | 11.71 | 4.61-70.6% | 4.24 | 3.44-58.4% |
| Cash from Operating Activities | -93.48-165.7% | -88.21 | -75.17 | -90.50 | 142.21 | -62.47 | -60.34 | -121.66 |
| Capital Expenditures | -0.27 | -0.87 | -0.97 | -0.33 | -0.04 | -0.66 | -1.33 | -1.10 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase or Sale of Investments | 78.92+88.8% | -155.07-432.9% | 119.92+47.8% | -97.19 | 41.81 | 46.58-33.0% | 81.15 | -196.01 |
| Purchase of Investments | -63.37 | -313.43 | -42.61 | -236.14 | -138.99 | -127.55 | -105.21 | -337.04 |
| Sale Or Maturity of Investments | 142.29-21.3% | 158.37-9.1% | 162.53-12.8% | 138.94-1.5% | 180.80-6.9% | 174.13-25.7% | 186.35+51.3% | 141.03+27.6% |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | 78.65+88.3% | -155.93-439.6% | 118.95+49.0% | -97.53 | 41.77 | 45.92-33.0% | 79.82 | -197.11 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Dividends (Cash Flow) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 3.69+1130.0% | 359.21+29586.8% | 1.18-95.5% | 2.13-22.5% | 0.30-99.9% | 1.21-96.9% | 26.14-92.5% | 2.75-98.0% |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 3.69+1130.0% | 359.21+29586.8% | 1.18-95.5% | 2.13-22.5% | 0.30-99.9% | 1.21-96.9% | 26.14-92.5% | 2.75-98.0% |
| Proceedsfrom Stock Options | -1.18 | 358.36+44695.0% | -0.01-100.0% | 0.63+152.0% | -0.08-100.0% | 0.80-97.8% | 25.01-92.7% | 0.25-99.8% |
| Issuance or Reduction of Debt, Net | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Activities Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Financing Activities | 3.69+1130.0% | 359.21+29586.8% | 1.18-95.5% | 2.13-22.5% | 0.30-99.9% | 1.21-96.9% | 26.14-92.5% | 2.75-98.0% |
| Net Change in Cash | -11.14-106.0% | 115.07 | 44.96-1.4% | -185.89 | 184.28-15.2% | -15.35-120.5% | 45.62 | -316.01-6177.1% |
| Free Cash Flow | -93.75-165.9% | -89.08 | -76.14 | -90.83 | 142.17 | -63.14 | -61.67 | -122.76 |
Revenue breakdown
USD millions, so a column adds up to the income statement. Share is of the latest year in that split. The change is versus the older year shown, not TTM.
| Name | 2024 | 2025 | vs 2024 | 2025 share |
|---|---|---|---|---|
| Pharmaceutical Preparations | 7.00 | 218.71 | +3024.4% | 100.0% |
| Total | 7.00 | 218.71 | +3024.4% | 100.0% |
| Name | 2024 | 2025 | vs 2024 | 2025 share |
|---|---|---|---|---|
| United States | 7.00 | 218.71 | +3024.4% | 100.0% |
| Total | 7.00 | 218.71 | +3024.4% | 100.0% |
Short interest
shares short against float, oldest to newest| Settlement | Of float | Shares short | Float | Avg volume |
|---|---|---|---|---|
| 2026-10-30 | 9.12% | 8.2M | 90.3M | 812.62K |
| 2026-10-15 | 10.08% | 9.1M | 90.1M | 789.11K |
| 2026-09-30 | 10.19% | 9.2M | 90.1M | 848.24K |
| 2026-09-15 | 11.03% | 9.9M | 90.1M | 944.50K |
| 2026-08-31 | 11.14% | 10.1M | 90.7M | 1.09M |
| 2026-08-14 | 11.47% | 10.4M | 90.7M | 1.07M |
| 2026-07-31 | 11.09% | 10.1M | 91.2M | 1.11M |
| 2026-07-15 | 10.65% | 9.6M | 89.9M | 1.16M |
| 2026-06-30 | 11.50% | 10.3M | 89.9M | 1.36M |
| 2026-06-15 | 11.83% | 10.6M | 89.9M | 1.25M |
| 2026-05-29 | 13.65% | 11.3M | 83.1M | 1.16M |
| 2026-05-15 | 14.10% | 11.7M | 83.0M | 1.17M |
| 2026-04-30 | 14.17% | 11.7M | 82.6M | 1.18M |
| 2026-04-15 | 12.79% | 10.6M | 82.6M | 1.14M |
| 2026-03-31 | 11.81% | 9.8M | 82.6M | 921.86K |
| 2026-03-13 | 11.77% | 9.7M | 82.6M | 887.83K |
| 2026-02-27 | 11.78% | 9.7M | 82.6M | 901.91K |
| 2026-02-13 | 12.10% | 10.0M | 82.6M | 913.87K |
| 2026-01-30 | 11.12% | 9.3M | 83.8M | 925.10K |
| 2026-01-15 | 10.39% | 8.7M | 83.8M | 1.03M |
Option chain
Expiry 2026-11-20 · underlying 31.49, quoted 12 Nov 15:59 ET · ATM 32.50
Option quotes 12 Nov 13:07 ET. A date on a row is older than the last session (12 Nov). 28 rows.
Implied move 9.84% into expiry (call 1.300 + put 1.800 = 3.100 on 31.49)
Put/call open interest 1.00 (308 puts / 307 calls) · Put/call volume 1.00 (1 puts / 1 calls)
IV change is points against the prior close.
| Type | Strike | Money | Bid | Ask | Last | Chg | IV | Open int | Volume | Last size | Delta | Theta | Vega |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| call 1 Jan | 17.50 | ITM | 12.00 | 16.50 | 0.00 | 0.00 | 554.7% +168.3 | 0 | 0 | 0 | 0.907 | -0.191 | 0.008 |
| put 1 Jan | OTM | 0.00 | 4.90 | 0.00 | 0.00 | 382.2% 0.0 | 0 | 0 | 0 | -0.092 | -0.184 | 0.008 | |
| call 1 Jan | 20.00 | ITM | 9.50 | 14.00 | 0.00 | 0.00 | 464.7% +146.8 | 0 | 0 | 0 | 0.887 | -0.181 | 0.009 |
| put 1 Jan | OTM | 0.00 | 4.90 | 0.00 | 0.00 | 314.9% 0.0 | 0 | 0 | 0 | -0.112 | -0.174 | 0.009 | |
| call 1 Jan | 22.50 | ITM | 7.00 | 11.30 | 0.00 | 0.00 | 369.1% +112.5 | 0 | 0 | 0 | 0.861 | -0.169 | 0.010 |
| put 1 Jan | OTM | 0.00 | 4.90 | 0.00 | 0.00 | 254.7% 0.0 | 0 | 0 | 0 | -0.137 | -0.162 | 0.010 | |
| call 1 Jan | 25.00 | ITM | 4.50 | 8.80 | 0.00 | 0.00 | 298.6% +98.4 | 0 | 0 | 0 | 0.826 | -0.154 | 0.012 |
| put 1 Jan | OTM | 0.00 | 4.90 | 0.00 | 0.00 | 199.4% 0.0 | 0 | 0 | 0 | -0.172 | -0.147 | 0.012 | |
| call 1 Jan | 27.50 | ITM | 2.00 | 6.50 | 0.00 | 0.00 | 244.9% +98.5 | 0 | 0 | 0 | 0.771 | -0.133 | 0.014 |
| put 1 Jan | OTM | 0.00 | 4.30 | 0.00 | 0.00 | 146.4% 0.0 | 0 | 0 | 0 | -0.229 | -0.130 | 0.014 | |
| call 11 Nov | 30.00 | ITM | 0.20 | 4.90 | 3.26 | 0.00 | 229.3% +101.8 | 56 | 0 | 0 | 0.640 | -0.142 | 0.017 |
| put 10 Nov | OTM | 0.10 | 1.80 | 0.60 | 0.00 | 91.9% -35.6 | 145 | 0 | 0 | -0.360 | -0.139 | 0.017 | |
| call 10 Nov | 32.50 | ATM | 0.10 | 2.50 | 1.25 | 0.00 | 159.0% +17.5 | 32 | 0 | 0 | 0.482 | -0.168 | 0.018 |
| put | ATM | 1.05 | 2.55 | 1.60 | -0.40 | 108.3% -33.3 | 152 | 1 | 1 | -0.518 | -0.164 | 0.018 | |
| call | 35.00 | OTM | 0.05 | 3.30 | 0.05 | -0.35 | 207.0% 0.0 | 66 | 1 | 1 | 0.423 | -0.240 | 0.018 |
| put 29 Oct | ITM | 1.00 | 5.10 | 2.80 | 0.00 | 157.5% -49.5 | 3 | 0 | 0 | -0.577 | -0.236 | 0.018 | |
| call 10 Nov | 37.50 | OTM | 0.00 | 3.50 | 0.15 | 0.00 | 246.1% 0.0 | 59 | 0 | 0 | 0.382 | -0.277 | 0.018 |
| put 2 Oct | ITM | 3.50 | 8.30 | 3.80 | 0.00 | 236.1% -10.1 | 4 | 0 | 0 | -0.618 | -0.273 | 0.018 | |
| call 28 Oct | 40.00 | OTM | 0.00 | 4.90 | 0.20 | 0.00 | 272.2% 0.0 | 43 | 0 | 0 | 0.354 | -0.296 | 0.018 |
| put 14 Oct | ITM | 6.00 | 10.80 | 6.80 | 0.00 | 269.6% -10.3 | 4 | 0 | 0 | -0.647 | -0.303 | 0.017 | |
| call 21 Oct | 42.50 | OTM | 0.00 | 4.10 | 0.64 | 0.00 | 191.7% 0.0 | 12 | 0 | 0 | 0.178 | -0.147 | 0.012 |
| put 1 Jan | ITM | 8.50 | 13.30 | 0.00 | 0.00 | 299.1% +107.4 | 0 | 0 | 0 | -0.822 | -0.143 | 0.012 | |
| call 22 Oct | 45.00 | OTM | 0.00 | 0.10 | 0.45 | 0.00 | 114.4% 0.0 | 19 | 0 | 0 | 0.045 | -0.031 | 0.005 |
| put 1 Jan | ITM | 11.00 | 15.80 | 0.00 | 0.00 | 325.6% +191.9 | 0 | 0 | 0 | -0.957 | -0.031 | 0.004 | |
| call 22 Oct | 47.50 | OTM | 0.00 | 0.75 | 0.30 | 0.00 | 149.5% 0.0 | 12 | 0 | 0 | 0.039 | -0.037 | 0.004 |
| put 1 Jan | ITM | 13.50 | 18.30 | 0.00 | 0.00 | 349.7% +200.1 | 0 | 0 | 0 | -0.961 | -0.032 | 0.004 | |
| call 15 Oct | 50.00 | OTM | 0.00 | 4.90 | 0.50 | 0.00 | 160.1% 0.0 | 2 | 0 | 0 | 0.036 | -0.037 | 0.004 |
| put 1 Jan | ITM | 16.00 | 20.80 | 0.00 | 0.00 | 371.7% +207.5 | 0 | 0 | 0 | -0.964 | -0.033 | 0.004 | |
| call 19 Oct | 55.00 | OTM | 0.00 | 4.90 | 0.55 | 0.00 | 186.2% 0.0 | 6 | 0 | 0 | 0.032 | -0.039 | 0.003 |
| put 1 Jan | ITM | 21.00 | 25.80 | 0.00 | 0.00 | 411.1% +220.3 | 0 | 0 | 0 | -0.968 | -0.034 | 0.003 |
Latest SEC filings
30| Filed | Form | Description | Period | Link |
|---|---|---|---|---|
| 2026-11-03 | S-8 | Initial registration statement for securities to be offered to employees pursuant to employee benefit plans | SEC | |
| 2026-11-03 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-09-30 | SEC |
| 2026-11-03 | 8-K | Current report | 2026-11-03 | SEC |
| 2026-10-08 | 4 | Statement of changes in beneficial ownership of securities | 2026-10-06 | SEC |
| 2026-10-06 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-08-14 | SCHEDULE 13G | SEC | ||
| 2026-08-04 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-06-30 | SEC |
| 2026-08-04 | 8-K | Current report | 2026-08-04 | SEC |
| 2026-07-31 | SCHEDULE 13G | SEC | ||
| 2026-07-09 | 4 | Statement of changes in beneficial ownership of securities | 2026-07-07 | SEC |
| 2026-07-07 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-06-23 | 8-K | Current report | 2026-06-16 | SEC |
| 2026-06-18 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-16 | SEC |
| 2026-06-18 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-16 | SEC |
| 2026-06-18 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-16 | SEC |
| 2026-06-18 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-16 | SEC |
| 2026-06-18 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-16 | SEC |
| 2026-06-18 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-16 | SEC |
| 2026-06-10 | 8-K | Current report | 2026-06-08 | SEC |
| 2026-06-09 | 424B5 | SEC | ||
| 2026-06-08 | 424B5 | SEC | ||
| 2026-06-05 | 3 | Initial statement of beneficial ownership of securities | 2026-03-18 | SEC |
| 2026-06-03 | 8-K | Current report | 2026-06-03 | SEC |
| 2026-06-01 | 8-K | Current report | 2026-06-01 | SEC |
| 2026-05-15 | SCHEDULE 13G/A | SEC | ||
| 2026-05-05 | 8-K | Current report | 2026-05-05 | SEC |
| 2026-05-05 | 424B5 | SEC | ||
| 2026-05-05 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers | SEC | |
| 2026-05-05 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-03-31 | SEC |
| 2026-05-05 | 8-K | Current report | 2026-05-05 | SEC |
Insider activity by month
| Month | Bought | Buys | Sold | Sells |
|---|---|---|---|---|
| 2026-11 | 0 | 0 | 0 | 0 |
| 2026-10 | 0 | 0 | 985.40K | 1 |
| 2026-09 | 0 | 0 | 0 | 0 |
| 2026-08 | 0 | 0 | 0 | 0 |
| 2026-07 | 0 | 0 | 382.13K | 1 |
| 2026-06 | 0 | 0 | 0 | 0 |
| 2026-05 | 0 | 0 | 0 | 0 |
| 2026-04 | 0 | 0 | 0 | 0 |
| 2026-03 | 1.65M | 1 | 0 | 0 |
| 2026-02 | 0 | 0 | 0 | 0 |
| 2026-01 | 0 | 0 | 0 | 0 |
| 2025-12 | 0 | 0 | 0 | 0 |
| 2025-11 | 0 | 0 | 0 | 0 |
Institutional holders
| Manager | % owned |
|---|---|
| FMR LLC | 15.00% |
| BlackRock, Inc. | 9.35% |
| Jupiter Topco LLC | 9.02% |
| Capital Research Global Investors | 5.54% |
| BAKER BROS. ADVISORS LP | 5.27% |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.35% |
| STATE STREET CORP | 4.07% |
| Logos Global Management LP | 3.16% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 2.86% |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 2.85% |
Funds
| Fund | % owned |
|---|---|
| SMALLCAP World Fund Inc | 5.47% |
| Fidelity Growth Company Fund | 4.90% |
| VANGUARD TOTAL STOCK MARKET INDEX FUND | 3.12% |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 2.43% |
| iShares Russell 2000 ETF | 2.26% |
| Fidelity Growth Company K6 Fund | 1.40% |
| Fidelity Series Growth Company Fund | 1.14% |
| Janus Henderson Triton Fund | 1.13% |
| VANGUARD EXTENDED MARKET INDEX FUND | 1.10% |
| Fidelity Small Cap Index Fund | 0.96% |
OakChart. IDYA. Cached 15 minutes. Terms